Research Topics
Species | Marc DebouverieSummaryAffiliation: CHU de Nancy Country: France Publications
| Collaborators
|
Detail Information
Publications
Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patientRadu Tanasescu
J Neurol 251:762-3. 2004
Validity of a French version of the fatigue impact scale in multiple sclerosisM Debouverie
Department of Neurology, Central Hospital, 54000 Nancy, France
Mult Scler 13:1026-32. 2007..There is no objective scale for assessing fatigue in French MS patients. The objective of this study was to adapt an English language scale for use with French patients...
A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetateM Debouverie
Hopital Central, CHU Nancy, Nancy, France
Eur J Neurol 14:1266-74. 2007..1 respectively). Adverse events were reported by 179 patients, leading to discontinuation of treatment in 10 patients. Patients with RRMS to whom beta-interferons cannot be prescribed can benefit from treatment with glatiramer acetate...
Increasing incidence of multiple sclerosis among women in Lorraine, Eastern FranceM Debouverie
Department of Neurology, Central Hospital, 54000 Nancy, France, EA 4003, Nancy Universite, School of Public Health, Faculte de Medecine, avenue de la Forêt de Haye, 54500 Vandoeuvre les Nancy, France
Mult Scler 13:962-7. 2007..The increase in incidence of MS between 1990 and 2002, mostly in women, was not related to better ascertainment of patients with mild disability...
[The organisation of health care and epidemiology of multiple sclerosis in France]M Debouverie
Service de Neurologie, Hopital Central, 29 Avenue du Marechal de Lattre de Tassigny, 54035 Nancy, France
Rev Neurol (Paris) 163:637-45. 2007....
Physical dimension of fatigue correlated with disability change over time in patients with multiple sclerosisMarc Debouverie
Dept of Neurology, Central Hospital, 54000 Nancy, France
J Neurol 255:633-6. 2008..A patient's perceived fatigue may be not only a clinically and psychosocially meaningful outcome but also a predictor of objective outcomes such as changes in disability status at three years...
Multiple sclerosis with a progressive course from onset in Lorraine-Eastern FranceM Debouverie
Dept of Neurology, Central Hospital, 54000, Nancy, France
J Neurol 254:1370-5. 2007..We did not find any significant unfluence of sex, age at onset, or symptoms at onset on the time from MS onset to assignment of scores 6 or 7 or on the time from the assignment of a score of 6 to the assignment of a score of 7...
Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatmentM Debouverie
Department of Neurology, Central Hospital, 54000 Nancy, France
Mult Scler 13:626-31. 2007..9 versus +0.3; P=0.03) for patients with RRMS. We found that mitoxantrone treatment induces stable disease up to two years after discontinuation of mitoxantrone therapy. In the third year, patients without DMT deteriorated...
More severe disability of North Africans vs Europeans with multiple sclerosis in FranceM Debouverie
Department of Neurology, Central Hospital, Nancy, France
Neurology 68:29-32. 2007..To compare the clinical disease progression in European (E) and North African (NA) patients with multiple sclerosis (MS) patients in France...
Natural history of multiple sclerosis in a population-based cohortM Debouverie
Department of Neurology, Central Hospital, Nancy, France
Eur J Neurol 15:916-21. 2008..We sought to identify predictive clinical factors of disability during initial course in multiple sclerosis (MS) patients...
Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosisM Debouverie
Department of Neurology, Hopital Central, Nancy, France
Mult Scler 10:407-12. 2004..The aim of this study was to investigate the use of mitoxantrone in clinical practice, and especially to describe predictive parameters of its effectiveness under these conditions...
Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatientsM Debouverie
Department of Neurology, Central Hospital, Nancy, France
Mult Scler 15:251-7. 2009..The aim was to compare the natural history of a population of patients followed in a MS centre (MSC) with patients followed outside a MS centre (NMSC)...
[Reconsidering fatigue at the onset of multiple sclerosis]M Debouverie
Service de Neurologie, Hopital Central, 29, Avenue du Marechal de Lattre de Tassigny, 54035 Nancy, France
Rev Neurol (Paris) 165:S135-44. 2009..As seen above, some tools do not allow for multi-dimensional assessment of fatigue. The EMIF-SEP scale is useful in that it allows for qualitative and quantitative assessment of fatigue...
Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, FranceM Debouverie
Department of Neurology, Central Hospital, 54000 Nancy, France
J Neurol Sci 286:14-7. 2009..The data were very different for the time between the assignment of scores of 4 and 6, since the median times were not influenced by any of the predicting variables...
Cancer and multiple sclerosis in the era of disease-modifying treatmentsChristine Lebrun
Service de Neurologie, CHU Pasteur, 30 Voie Romaine, 06002 Nice, France
J Neurol 258:1304-11. 2011..This result could influence the attitude of the medical profession with respect to the benefit to risk ratio when proposing DMT to MS patients...
Clinical parameters to predict response to interferon in relapsing multiple sclerosisA Fromont
Department of Neurology, University Hospital of Dijon, Dijon, France
Neuroepidemiology 31:150-6. 2008..To identify clinical parameters of response to beta-interferon (IFN-beta) in relapsing-remitting multiple sclerosis (RRMS) from an East France cohort...
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosisChristine Lebrun
Service de Neurologie, CHU Pasteur, 06002 Nice, France
Mult Scler 14:399-405. 2008..From 1 January 1995 to 30 June 2006, we collected and studied the profile of 7,418 MS patients gathered from nine French MS centers. We evaluated the incidence of cancer in a Cancer Risk In MS Cohort...
Integration of cognitive impairment in the expanded disability status scale of 215 patients with multiple sclerosisHélène Brissart
Department of Neurology, Hopital Central, Nancy, France
Eur Neurol 64:345-50. 2010..Estimates of the prevalence of cognitive impairment among patients with multiple sclerosis (MS) range between 40 and 70%. The current cerebral functional system (CFS) of the Expanded Disability Status Scale (EDSS) is subjective...
[Ethical approach to informed consent for participation in clinical studies in acute cerebral infarct]X Ducrocq
Service de Neurologie, Hopital Central, Nancy
Presse Med 29:1335-40. 2000..Specifically, we examined comprehension and consequences of informed consent procedures in the field of stroke, characterized by an emergency setting, cognitive impairment and poor prognosis...
Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic strokeX Ducrocq
Service de Neurologie, Centre Hospitalier Universitaire, Hopital Central, avenue de Lattre de Tassigny, CO 34, 54035 Nancy Cedex
J Neuroradiol 32:26-32. 2005..Intra-arterial fibrinolysis began significantly later than IV fibrinolysis but it gave non-significantly better results in this prematurely terminated study...
Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort studyYann Mikaeloff
Assistance Publique Hopitaux de Paris, Service de Neurologie, Pédiatrique, Hopital Bicetre, INSERM U802, Universite Paris Sud 11, Le Kremlin Bicetre, France
Eur J Paediatr Neurol 12:205-9. 2008..In the absence of randomized controlled trials to support therapeutic decisions in pediatric MS (multiple sclerosis), comparative observational studies based on the real practice of physicians are important tools...
Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patientsH Zephir
Department of Neurology, , CHRU of Lille, 59037, Lille, Cedex, France
J Neurol Sci 218:73-7. 2004..To date, no treatment is approved for PPMS and we therefore propose a trial to test the use of CYC treatment early in the course of the disease in PPMS patients with disability progression...
[Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year]S Ory
Service de Neurologie, Hopital Pontchaillou, rue Henri Le Guilloux, 35033 Rennes Cedex, France
Rev Neurol (Paris) 164:1028-34. 2008..In an observational multicenter study, we analyzed retrospectively 30 patients with malignant form of multiple sclerosis (MS) treated with mitoxantrone the year following the first neurological event...
Fatigue in multiple sclerosis is related to disability, depression and quality of lifeS Pittion-Vouyovitch
Department of Neurology, Central Hospital, 54000 Nancy, France
J Neurol Sci 243:39-45. 2006..These data confirm that fatigue is correlated with disability, but cognitive and psychological dimensions of fatigue remain independent. Fatigue is also associated with depression and quality of life...
Neuromyelitis optica in France: a multicenter study of 125 patientsN Collongues
Department of Neurology, University Hospital of Strasbourg, 67091 Strasbourg, France
Neurology 74:736-42. 2010..There have been few epidemiologic studies on neuromyelitis optica (NMO) and none used the recent 2006 diagnostic criteria. Here we describe the clinical, laboratory, MRI, and disability course of NMO in a French cohort of 125 patients...
Geographic variations of multiple sclerosis in FranceAgnes Fromont
Department of Neurology, University Hospital of Dijon, and Centre of Epidemiology of the Populations, Burgundy University, 3 rue du Faubourg Raines, 21000 Dijon, France
Brain 133:1889-99. 2010....
Mutations of the ANG gene in French patients with sporadic amyotrophic lateral sclerosisAgathe Paubel
INSERM U930, Université François Rabelais Tours, CHRU de Tours, Faculte de Medecine, 10 boulevard Tonnelle, BP3223, 37032 Tours Cedex, France
Arch Neurol 65:1333-6. 2008..However, the cellular and molecular mechanisms that link ANG, a multidomain protein, to ALS are still unknown...
[Fatigue scales used in multiple sclerosis]M Debouverie
Service de Neurologie, , 54035 Nancy Cedex, France
Rev Neurol (Paris) 158:1139-43. 2002
Primary progressive multiple sclerosis: a comparative study of the diagnostic criteriaJ de Seze
Department of Neurology, Hopital Civil, Strasbourg, France
Mult Scler 13:622-5. 2007..3%) had PPMS. Our findings indicate that the revised McDonald criteria are more sensitive than the original McDonald criteria, but less sensitive than the Thompson criteria...
Cerebral venous thrombosis in four patients with multiple sclerosisN Vandenberghe
Departments of Neurology and Neuroradiology, Nancy, France
Eur J Neurol 10:63-6. 2003..Minor sequelae were noticed in two patients. The pathogenesis underlying the occurrence of CVT in MS patients remains unclear and we discuss the relationship between lumbar puncture, steroid treatment and CVT...
[Cognitive rehabilitation in multiple sclerosis: preliminary results and presentation of a new program, PROCOG-SEP]H Brissart
Service de Neurologie, Hopital Central, CHU de Nancy, Avenue du Marechal de Lattre de Tassigny, 54035 Nancy Cedex, France
Rev Neurol (Paris) 166:406-11. 2010..The evidence-based program proposes exercises to both stimulate preserved functions and develop new abilities compensating for cognitive disabilities...
Natural history of multiple sclerosis with childhood onsetChristel Renoux
Hopital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France
N Engl J Med 356:2603-13. 2007..The course and prognosis of childhood-onset multiple sclerosis have not been well described...
Acute fulminant demyelinating disease: a descriptive study of 60 patientsJerome De Seze
Departement de Neurologie, Hopital Civil, 1 Place de l Hopital, BP 426, 67091 Strasbourg Cedex, France
Arch Neurol 64:1426-32. 2007..To date, no clear criteria exist for ADEM, and the risk of subsequent evolution to multiple sclerosis (MS) remains unknown...
Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assayCatherine Massart
Unité d Hormonologie, CHU Rennes, France
Clin Chim Acta 391:98-101. 2008..Neutralizing antibodies (NAb) against interferon beta (IFNbeta) reduce treatment efficacy in patients with multiple sclerosis (MS)...
